Cellular Biomedicine Group Inc. (CBMG) is a clinical- stage biopharmaceutical firm involved in developing effective immunotherapies for cancer and stem cell therapies for degenerative diseases. It has recently completed expansion of its stem cell and chimeric antigen receptor T cell (CAR T cell) therapy facility.
The new set up at Huishan High Tech Park in Wuxi, China, is equipped with six independent production lines with the capability of producing and banking low endotoxin high transfection rate plasmids, and high titer automated and purified virus with stringent quality control. Within the total facility of 30,000 square feet, approximately 20,000 square feet will be dedicated to advanced stem cell culturing, centralized plasmid and viral vector production, cell banking and development of reagents.
Two Phase I human clinical trials were recently commenced by CBMG in China using CAR-T for treating relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia and refractory diffuse large B-cell lymphoma. The firm was also recently awarded US$2.29 million from the California Institute for Regenerative Medicine to support pre-clinical studies of AlloJoinTM for knee osteoarthritis in the United States.
The firm intends to utilize all its facilities for treating upto 10,000 cancer and knee osteoarthritis patients each per year.